Weather New York, NY +71°F

Allergan Inc

Doctors Without Borders Protests High Cost Of Vaccines

Pfizer chief Ian Read's pay falls 23%

Pfizer said that net compensation of chief executive officer Ian Read declined 23% in 2015 driven by a drop in stock awards. The chief's net compensation amounted to $18 million in 2015.

Read Full Article
Valeant Pharmaceuticals International Inc.

Valeant to drop deal-making in near term to cut debt, boost stock

Valeant Pharmaceuticals International Inc (VRX.TO) is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.

Read Full Article
Valeant Pharmaceuticals International Inc.

Valeant ready to raise Allergan bid to at least $200/share

Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) on Monday said in a letter to Allergan Inc's (AGN.N) board of directors that it was prepared to raise its offer to at least $200 per share but stopped short of doing so.

Read Full Article
A sample of Botox

Actavis plans new merger approach for Allergan - sources

Actavis Plc (ACT.N) plans to approach Allergan Inc (AGN.N) again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

Read Full Article
Valeant Pharmaceuticals International Inc.

ISS urges Allergan to give investors vote, questions credibility

Prominent investor shareholder advisory firm ISS called on Allergan Inc to give its shareholders a chance to vote on any large, buyout-blocking acquisitions and said the company's board faced a credibility problem, according to a report seen by Reuters.

Read Full Article
Botox

Shareholder T. Rowe Price urges Allergan to hold off on deals

T. Rowe Price, the second largest shareholder in Allergan Inc (AGN.N), said on Friday that it wants the company to hold off on making major moves before a Dec. 18 special shareholder meeting, and criticized the board on its corporate governance.

Read Full Article
Valeant Pharmaceuticals International Inc.

ValueAct returns to Valeant board, plans to raise stake

Hedge fund ValueAct Capital said on Thursday it would return to the board of directors of Valeant Pharmaceuticals International Inc, which is pursuing a hostile takeover offer for Allergan Inc, and that it planned to increase its stake in the company.

Read Full Article
Ackman

Facing shareholder demands, Allergan calls special meeting for December 18

Allergan Inc said on Tuesday that it has scheduled a special shareholders meeting for Dec. 18, when activist investor Bill Ackman, who supports a hostile bid for the company by Valeant Pharmaceuticals Inc, will attempt to oust most of its board.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics